ICOS and neoplasm: Alongside changes in target expression, significant increases in serum IFNγ levels and T-cell activation/function in tumor-draining lymph nodes were observed following treatment with the mIgG1 anti-ICOS mAb and the anti-PD-1 mAb combined (Supplementary Fig. S10C and S10D).